We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
- Authors
Kröger, Nicolaus; Zabelina, Tatjana; Krüger, William; Renges, Helmut; Stute, Norbert; Dürken, Matthias; Graf von Finkenstein, Friedrich; Erttmann, Rolf; Kabisch, Hartmut; Schafhausen, Philipe; Jaburg, Nicole; Löliger, Cornelius; Zander, Axel R; Kröger, N; Zabelina, T; Krüger, W; Renges, H; Stute, N; Dürken, M; Graf von Finkenstein, F
- Abstract
To reduce the incidence of GvHD and the rate of graft failure in unrelated stem cell transplantation, we incorporate anti-thymocyte globulin in the preparative regimen in 98 patients with hematological or inherited storage disease. The median age was 32 years (range: 1-56) and 84 patients underwent transplantation from HLA-A,-B and DR identical donor, while in 14 patients the donor were mismatched either in HLA- A, -B or -DR locus. Only one patient with chronic myelocytic leukemia (CML) and blast crisis had a primary graft failure (1%). Grade II-IV acute GvHD occurred in 37 patients (37%), grade III/IV GvHD developed in 15 patients (15%). Chronic GvHD was observed in 29%, and only 12 patients had extensive GvHD (17%). After a median follow-up of 34 months (range, 9-90), the estimated overall survival at 3 years for all patients is 58% (CI 95%: 48%-68%), and the estimated disease-free survival at 3 years is 49% (CI 95%: 38%-60%). For patients with CML transplanted in first chronic phase or accelerated phase (n=40), the estimated overall survival at 3 years is 70% (CI 95%: 56%-84%), and the estimated disease-free survival at 3 years is 58% (CI 95%: 17%-85%). ATG in unrelated stem cell transplantation reduces the risk of severe acute and chronic GvHD and of graft failure without an obvious increase of severe infection. Further follow-up is mandatory to determine the incidence of late relapse.
- Subjects
GRAFT versus host disease; STEM cells; TRANSPLANTATION of organs, tissues, etc.; MYELOID leukemia; GLOBULINS; ORGAN donation
- Publication
Annals of Hematology, 2001, Vol 80, Issue 4, p209
- ISSN
0939-5555
- Publication type
journal article
- DOI
10.1007/s002770000269